or Try an Advanced Search...

    Technical Analysis for ITOS - iTeos Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 15.01 1.15% 0.17
    ITOS closed up 1.15 percent on Monday, July 1, 2024, on 36 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Flat Flat
    Historical ITOS trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish 0.00%
    Inside Day Range Contraction 0.00%
    Fell Below 50 DMA Bearish 1.15%
    180 Bearish Setup Bearish Swing Setup 1.15%
    Outside Day Range Expansion 1.15%
    Oversold Stochastic Weakness -3.16%
    Bullish Engulfing Bullish -0.20%
    Crossed Above 50 DMA Bullish -0.20%
    Outside Day Range Expansion -0.20%
    Oversold Stochastic Weakness -0.20%
    Older End-of-Day Signals for ITOS ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 6 hours ago
    Up 3% about 10 hours ago
    Up 2% about 10 hours ago
    Up 1% about 10 hours ago
    Rose Above 50 DMA about 11 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ITOS Chart by TradingView
    Basic chart:

    Profile

    Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains. The company was founded in 2011 and is based in Cambridge, Massachusetts with an additional location in Gosselies, Belgium.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Adenosine Therapeutics For Cancer

    Is ITOS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 18 iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC
    Jun 17 iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
    Jun 5 Should Shareholders Reconsider iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package?
    May 10 iTeos Therapeutics signs agreement for $120M registered direct offering
    May 10 iTeos Therapeutics reports Q1 results
    May 10 iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
    May 10 iTeos Therapeutics Announces $120 Million Registered Direct Offering
    May 10 iTeos shares jump on TIGIT update; Acelyrin swaps CEOs
    Apr 7 iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
    Mar 6 Recap: ITeos Therapeutics Q4 Earnings
    See more ITOS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 18.75
    52 Week Low 8.2
    Average Volume 496,560
    200-Day Moving Average 11.74
    50-Day Moving Average 14.97
    20-Day Moving Average 15.81
    10-Day Moving Average 14.96
    Average True Range 0.74
    RSI (14) 44.44
    ADX 25.99
    +DI 15.35
    -DI 21.08
    Chandelier Exit (Long, 3 ATRs) 15.29
    Chandelier Exit (Short, 3 ATRs) 16.50
    Upper Bollinger Bands 17.61
    Lower Bollinger Band 14.02
    Percent B (%b) 0.28
    BandWidth 22.72
    MACD Line -0.23
    MACD Signal Line -0.05
    MACD Histogram -0.1774
    Fundamentals Value
    Market Cap 537.13 Million
    Num Shares 35.8 Million
    EPS -1.75
    Price-to-Earnings (P/E) Ratio -8.58
    Price-to-Sales 5.87
    Price-to-Book 0.64
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 15.78
    Resistance 3 (R3) 15.80 15.57 15.65
    Resistance 2 (R2) 15.57 15.38 15.56 15.60
    Resistance 1 (R1) 15.29 15.25 15.43 15.27 15.56
    Pivot Point 15.06 15.06 15.13 15.05 15.06
    Support 1 (S1) 14.78 14.87 14.92 14.76 14.46
    Support 2 (S2) 14.55 14.74 14.54 14.42
    Support 3 (S3) 14.27 14.55 14.37
    Support 4 (S4) 14.25